Artisan Partners released its third-quarter 2025 investor letter, showing strong performance with its mid-cap funds outperforming the Russell Midcap Growth Index. The fund highlighted Veracyte, Inc. (VCYT) as a top stock pick, reporting a 4.66% one-month return and a market capitalization of $2.736 billion. Veracyte is a molecular diagnostics company experiencing 14% year-over-year revenue growth, driven by strong sales of its cancer tests. While not among the 30 most popular stocks among hedge funds, Veracyte’s growth potential is recognized, with 29 hedge fund portfolios holding the stock in the second quarter of 2025.

Read more at Yahoo Finance: Do You Believe in the Upside Potential of Veracyte (VCYT)